Refine
Year of publication
Document Type
- Article (83)
- Preprint (8)
- Conference Proceeding (3)
- Diploma Thesis (1)
- Working Paper (1)
Has Fulltext
- yes (96)
Is part of the Bibliography
- no (96)
Keywords
- SARS-CoV-2 (3)
- Accelerators & Beams (2)
- Atomic, Molecular & Optical (2)
- COVID-19 (2)
- NMR spectroscopy (2)
- Outcome (2)
- RNA (2)
- Stroke (2)
- hypoxia (2)
- 3years (1)
- ARDS (1)
- ASCT (1)
- Accelerators & storage rings (1)
- Anti-kaon–nucleon physics (1)
- Aortic valve (1)
- Aortic valve replacement (1)
- Atomic & molecular beams (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism spectrum disorder (1)
- B.1.1.7 (1)
- BI1361849 (1)
- Baryonic resonances (1)
- Beam loss (1)
- Blood flow restriction (1)
- Brain asymmetry (1)
- CHIP (1)
- COVID (1)
- CV9202 (1)
- CVID (1)
- Cardiac surgery (1)
- Cerebrovascular (1)
- Charge-transfer collisions (1)
- Circular accelerators (1)
- Circulating miRNA (1)
- Clinical Trials and Observations (1)
- Clinical competence (1)
- Clinical frailty scale (1)
- Clinical trial (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Coronary heart disease (1)
- Couch tracking (1)
- Covid19-nmr (1)
- Critical care (1)
- Crystal structure (1)
- Cue-P3 (1)
- DME (1)
- Devic disease (1)
- Devic syndrome (1)
- EEG (1)
- Echovirus-30 (1)
- Ejection fraction (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Endurance training (1)
- European Society for Immunodeficiencies (ESID) (1)
- Event related potentials (1)
- Experimental models of disease (1)
- FFPE (1)
- Fast-track (1)
- Fibre/foam sandwich radiator (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Frailty (1)
- Freezeout (1)
- GRAND-SLAM (1)
- German PID-NET registry (1)
- Gimbaled tracking (1)
- HAI‐1 (1)
- HGF (1)
- HIBCPP cells (1)
- Heavy-ion reactions (1)
- Hemispheric specialization (1)
- Heterogeneity (1)
- High-pressure (1)
- Hyperons (1)
- Hypofractionated radiotherapy (1)
- ICU (1)
- ILUVIEN (1)
- IgG substitution therapy (1)
- Immunomonitoring (1)
- Intensive care outcome (1)
- Ionisation energy loss (1)
- Kaonic nuclei (1)
- Language delay (1)
- Low & intermediate-energy accelerators (1)
- Low energy QCD (1)
- MLC tracking (1)
- Molecular biology (1)
- Multi-wire proportional drift chamber (1)
- Multianvil (1)
- Muscular diseases (1)
- Myeloid Neoplasia (1)
- N501Y (1)
- NADPH oxidase (1)
- NMO-IgG (1)
- NMR (1)
- Nervous system diseases (1)
- Neural network (1)
- Neurofeedback (1)
- Neuromyelitis optica (1)
- Non-small cell lung cancer (1)
- Normative modeling (1)
- Nox1 (1)
- NoxO1 (1)
- Nuclear astrophysics (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- Nucleus (1)
- Organ motion (1)
- PID prevalence (1)
- Partial wave analysis (1)
- Photon counting (1)
- Polarization (1)
- Prognostic models (1)
- Proton (1)
- RNA stability (1)
- RNA, long noncoding (1)
- Radiation detectors (1)
- Radiative capture (1)
- Randomized Controlled Trial (1)
- Rare-earth borate (1)
- Reactive oxygen species (1)
- Readmission (1)
- Response control (1)
- Retro-IDEAL (1)
- Robotic tracking (1)
- SLAM-seq (1)
- SWATH (1)
- Slow Cortical Potentials, SCP (1)
- Stenosis (1)
- Steroid (1)
- Strangeness (1)
- Superoxide (1)
- Sustained attention (1)
- TR (1)
- Telomere length (1)
- Telomeres (1)
- Terbium (1)
- Thrombosis (1)
- Tracking (1)
- Transient (1)
- Transient ischemic attack (1)
- Transition radiation detector (1)
- Trigger (1)
- VIGALL (1)
- VIP1 (1)
- Vertigo (1)
- Water balance (1)
- White blood cells (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- accident (1)
- adaptation (1)
- antibiotic therapy (1)
- aquaporin-4 (AQP4) antibody (1)
- arteriogenesis (1)
- autologous stem cell transplantation (1)
- available water capacity (1)
- biomarker (1)
- blood flow restriction (1)
- blood-cerebrospinal fluid barrier (1)
- bone healing (1)
- bone marrow mononuclear cells (1)
- bortezomib (1)
- breast tumor (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- circulating miRNA (1)
- clinical features (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- dE/dx (1)
- de novo transcription (1)
- depression (1)
- drought-stress (1)
- drug resistance (1)
- enterovirus (1)
- epidemiology (1)
- epigenomics (1)
- evolution (1)
- fecal microbiota transfer (1)
- forest site classification (1)
- fragment screening (1)
- genetic diversity (1)
- glioblastoma (1)
- graft-vs-host disease (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatitis C virus (HCV) (1)
- heteronuclear detection (1)
- human allogeneic hematopoietic cell transplantation (1)
- human decellularized dermis (1)
- human intestinal microbiota (1)
- hypertension, pulmonary (1)
- imaging (1)
- induced membrane (1)
- induction regimen (1)
- infections: pneumonia, TB, viral (1)
- injury (1)
- intrinsically disordered region (1)
- isotope labeling (1)
- kidney (1)
- large functional RNAs (1)
- lenalidomide (1)
- leukemia (1)
- lipid raft (1)
- lockdown (1)
- longitudinally extensive transverse myelitis (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magnetic resonance imaging (1)
- miR (1)
- miR-142-5p (1)
- miR-143-3p (1)
- miR-197-3p (1)
- miR-342-3p (1)
- miR-424-5p (1)
- microdosing (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- molecular adaptation (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular surveillance (1)
- monocytes (1)
- multiple myeloma (1)
- natural selection (1)
- neovascularization, physiologic (1)
- nonstructural proteins (1)
- obesity (1)
- p47phox (1)
- pediatric intensive care (1)
- peripheral artery disease (1)
- ppK − (1)
- pressure cycling technology (1)
- primary immunodeficiency (PID) (1)
- proliferation (1)
- protease inhibitor (1)
- proteome (1)
- recurrent optic neuritis (1)
- registry for primary immunodeficiency (1)
- renal failure (1)
- replicative fitness (1)
- resistance mutation (1)
- serine protease (NS3-4A) (1)
- site classification system (1)
- sleepiness (1)
- somatic mutations (1)
- spike mutation (1)
- strength training (1)
- structural proteins (1)
- structure constraints (1)
- trauma (1)
- tumor (1)
- tumor microenvironment (1)
- tumor‐associated macrophages (1)
- viral infection (1)
- x-ray techniques (1)
Institute
- Medizin (53)
- Physik (26)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- ELEMENTS (5)
- Geowissenschaften (5)
- Biochemie und Chemie (4)
- Frankfurt Institute for Advanced Studies (FIAS) (4)
- Informatik (4)
- Sonderforschungsbereiche / Forschungskollegs (3)
- Biochemie, Chemie und Pharmazie (2)
Background: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1), intended to induce targeted immune responses.
Methods: We describe a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy. Patients were stratified into three strata (1: non-squamous NSCLC, no epidermal growth factor receptor (EGFR) mutation, PR/SD after ≥4 cycles of platinum- and pemetrexed-based treatment [n = 16]; 2: squamous NSCLC, PR/SD after ≥4 cycles of platinum-based and non-platinum compound treatment [n = 8]; 3: non-squamous NSCLC, EGFR mutation, PR/SD after ≥3 and ≤ 6 months EGFR-tyrosine kinase inhibitor (TKI) treatment [n = 2]). Patients received intradermal BI1361849, local radiation (4 × 5 Gy), then BI1361849 until disease progression. Strata 1 and 3 also had maintenance pemetrexed or continued EGFR-TKI therapy, respectively. The primary endpoint was evaluation of safety; secondary objectives included assessment of clinical efficacy (every 6 weeks during treatment) and of immune response (on Days 1 [baseline], 19 and 61).
Results: Study treatment was well tolerated; injection site reactions and flu-like symptoms were the most common BI1361849-related adverse events. Three patients had grade 3 BI1361849-related adverse events (fatigue, pyrexia); there was one grade 3 radiation-related event (dysphagia). In comparison to baseline, immunomonitoring revealed increased BI1361849 antigen-specific immune responses in the majority of patients (84%), whereby antigen-specific antibody levels were increased in 80% and functional T cells in 40% of patients, and involvement of multiple antigen specificities was evident in 52% of patients. One patient had a partial response in combination with pemetrexed maintenance, and 46.2% achieved stable disease as best overall response. Best overall response was SD in 57.7% for target lesions.
Conclusion: The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
Trial registration: ClinicalTrials.gov identifier: NCT01915524.
In solid tumors, tumor‐associated macrophages (TAMs) commonly accumulate within hypoxic areas. Adaptations to such environments evoke transcriptional changes by the hypoxia‐inducible factors (HIFs). While HIF‐1α is ubiquitously expressed, HIF‐2α appears tissue‐specific with consequences of HIF‐2α expression in TAMs only being poorly characterized. An E0771 allograft breast tumor model revealed faster tumor growth in myeloid HIF‐2α knockout (HIF‐2αLysM−/−) compared with wildtype (wt) mice. In an RNA‐sequencing approach of FACS sorted wt and HIF‐2α LysM−/− TAMs, serine protease inhibitor, Kunitz type‐1 ( Spint1) emerged as a promising candidate for HIF‐2α‐dependent regulation. We validated reduced Spint1 messenger RNA expression and concomitant Spint1 protein secretion under hypoxia in HIF‐2α‐deficient bone marrow–derived macrophages (BMDMs) compared with wt BMDMs. In line with the physiological function of Spint1 as an inhibitor of hepatocyte growth factor (HGF) activation, supernatants of hypoxic HIF‐2α knockout BMDMs, not containing Spint1, were able to release proliferative properties of inactive pro‐HGF on breast tumor cells. In contrast, hypoxic wt BMDM supernatants containing abundant Spint1 amounts failed to do so. We propose that Spint1 contributes to the tumor‐suppressive function of HIF‐2α in TAMs in breast tumor development.
Leukemia cells reciprocally interact with their surrounding bone marrow microenvironment (BMM), rendering it hospitable to leukemia cell survival, for instance through the release of small extracellular vesicles (sEVs). In contrast, we show here that BMM deficiency of pleckstrin homology domain family M member 1 (PLEKHM1), which serves as a hub between fusion and secretion of intracellular vesicles and is important for vesicular secretion in osteoclasts, accelerates murine BCR-ABL1+ B-cell acute lymphoblastic leukemia (B-ALL) via regulation of the cargo of sEVs released by BMM-derived mesenchymal stromal cells (MSCs). PLEKHM1-deficient MSCs and their sEVs carry increased amounts of syntenin and syndecan-1, resulting in a more immature B-cell phenotype and an increased number/function of leukemia-initiating cells (LICs) via focal adhesion kinase and AKT signaling in B-ALL cells. Ex vivo pretreatment of LICs with sEVs derived from PLEKHM1-deficient MSCs led to a strong trend toward acceleration of murine and human BCR-ABL1+ B-ALL. In turn, inflammatory mediators such as recombinant or B-ALL cell–derived tumor necrosis factor α or interleukin-1β condition murine and human MSCs in vitro, decreasing PLEKHM1, while increasing syntenin and syndecan-1 in MSCs, thereby perpetuating the sEV-associated circuit. Consistently, human trephine biopsies of patients with B-ALL showed a reduced percentage of PLEKHM1+ MSCs. In summary, our data reveal an important role of BMM-derived sEVs for driving specifically BCR-ABL1+ B-ALL, possibly contributing to its worse prognosis compared with BCR-ABL1− B-ALL, and suggest that secretion of inflammatory cytokines by cancer cells in general may similarly modulate the tumor microenvironment.
Abstract: Neurophysiological measures of preparation and attention are often atypical in ADHD. Still, replicated findings that these measures predict which patients improve after Neurofeedback (NF), reveal neurophysiological specificity, and reflect ADHD-severity are limited. Methods: We analyzed children’s preparatory (CNV) and attentional (Cue-P3) brain activity and behavioral performance during a cued Continuous Performance Task (CPT) before and after slow cortical potential (SCP)-NF or semi-active control treatment (electromyogram biofeedback). Mixed-effects models were performed with 103 participants at baseline and 77 were assessed for pre-post comparisons focusing on clinical outcome prediction, specific neurophysiological effects of NF, and associations with ADHD-severity. Results: Attentional and preparatory brain activity and performance were non-specifically reduced after treatment. Preparatory activity in the SCP-NF group increased with clinical improvement. Several performance and brain activity measures predicted non-specific treatment outcome. Conclusion: Specific neurophysiological effects after SCP-NF were limited to increased neural preparation associated with improvement on ADHD-subscales, but several performance and neurophysiological measures of attention predicted treatment outcome and reflected symptom severity in ADHD. The results may help to optimize treatment.
Previous studies towards reduced oxygen availability have mostly focused on changes in total mRNA expression, neglecting underlying transcriptional and post-transcriptional events. Therefore, we generated a comprehensive overview of hypoxia-induced changes in total mRNA expression, global de novo transcription, and mRNA stability in monocytic THP-1 cells. Since hypoxic episodes often persist for prolonged periods, we further compared the adaptation to acute and chronic hypoxia. While total mRNA changes correlated well with enhanced transcription during short-term hypoxia, mRNA destabilization gained importance under chronic conditions. Reduced mRNA stability not only added to a compensatory attenuation of immune responses, but also, most notably, to the reduction in nuclear-encoded mRNAs associated with various mitochondrial functions. These changes may prevent the futile production of new mitochondria under conditions where mitochondria cannot exert their full metabolic function and are indeed actively removed by mitophagy. The post-transcriptional mode of regulation might further allow for the rapid recovery of mitochondrial capacities upon reoxygenation. Our results provide a comprehensive resource of functional mRNA expression dynamics and underlying transcriptional and post-transcriptional regulatory principles during the adaptation to hypoxia. Furthermore, we uncover that RNA stability regulation controls mitochondrial functions in the context of hypoxia.
Rationale: Steroid refractory graft-vs-host disease (sr-GvHD) represents a challenging complication after allogeneic hematopoietic cell transplantation (allo-HCT). Intestinal microbiota (IM) diversity and dysbiosis were identified as influencing factors for the development of acute GvHD. Fecal microbiota transfer (FMT) is hypothesized to restore IM dysbiosis, but there is limited knowledge about the significance of FMT in the treatment of sr-GvHD.
Objectives: We studied the effects of FMT on sr-GvHD in allo-HCT patients from two German tertiary clinical centers (n = 11 patients; period: March 2017 until July 2019). To assess safety and clinical efficacy, we analyzed clinical data pre- and post-FMT (day -14 to +30 relative to FMT). Moreover, IM were analyzed in donor samples and in a subset of patients pre- and post-FMT by 16S rRNA sequencing.
Results: Post-FMT, we observed no intervention-associated, systemic inflammatory responses and only minor side effects (5/11 patients: abdominal pain and transformation of peristalsis—each 3/11 and vomiting—1/11). Stool frequencies and volumes were significantly reduced [pre- vs post-FMT (d14): P < .05, respectively] as well as clear attenuation regarding both grading and staging of sr-GvHD was present upon FMT. Moreover, IM analyses revealed an increase of alpha diversity as well as a compositional shifts toward the donor post-FMT.
Conclusions: In our study, we observed positive effects on sr-GVHD after FMT without the occurrence of major adverse events. Although these findings are in line with published data on beneficial effects of FMT in sr-GvHD, further randomized clinical studies are urgently needed to better define the clinical validity including mode of action.
SARS-CoV-2 contains a positive single-stranded RNA genome of approximately 30 000 nucleotides. Within this genome, 15 RNA elements were identified as conserved between SARS-CoV and SARS-CoV-2. By nuclear magnetic resonance (NMR) spectroscopy, we previously determined that these elements fold independently, in line with data from in vivo and ex-vivo structural probing experiments. These elements contain non-base-paired regions that potentially harbor ligand-binding pockets. Here, we performed an NMR-based screening of a poised fragment library of 768 compounds for binding to these RNAs, employing three different 1H-based 1D NMR binding assays. The screening identified common as well as RNA-element specific hits. The results allow selection of the most promising of the 15 RNA elements as putative drug targets. Based on the identified hits, we derive key functional units and groups in ligands for effective targeting of the RNA of SARS-CoV-2.
Objective: We aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within 1 month from first dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany. Methods: A web-based questionnaire was e-mailed to all departments of neurology. We requested a report of cases of CVT occurring within 1 month of a COVID-19 vaccination. Other cerebral events could also be reported. Incidence rates of CVT were calculated by using official statistics of 9 German states. Results: A total of 45 CVT cases were reported. In addition, 9 primary ischemic strokes, 4 primary intracerebral hemorrhages, and 4 other neurological events were recorded. Of the CVT patients, 35 (77.8%) were female, and 36 (80.0%) were younger than 60 years. Fifty-three events were observed after vaccination with ChAdOx1 (85.5%), 9 after BNT162b2 (14.5%) vaccination, and none after mRNA-1273 vaccination. After 7,126,434 first vaccine doses, the incidence rate of CVT within 1 month from first dose administration was 0.55 (95% confidence interval [CI] = 0.38–0.78) per 100,000 person-months (which corresponds to a risk of CVT within the first 31 days of 0.55 per 100,000 individuals) for all vaccines and 1.52 (95% CI = 1.00–2.21) for ChAdOx1 (after 2,320,535 ChAdOx1 first doses). The adjusted incidence rate ratio was 9.68 (95% CI = 3.46–34.98) for ChAdOx1 compared to mRNA-based vaccines and 3.14 (95% CI = 1.22–10.65) for females compared to non-females. In 26 of 45 patients with CVT (57.8%), VITT was graded highly probable. Interpretation: Given an incidence of 0.02 to 0.15 per 100,000 person-months for CVT in the general population, these findings point toward a higher risk for CVT after ChAdOx1 vaccination, especially for women.
Background Reward processing has been proposed to underpin atypical social behavior, a core feature of autism spectrum disorder (ASD). However, previous neuroimaging studies have yielded inconsistent results regarding the specificity of atypicalities for social rewards in ASD. Utilizing a large sample, we aimed to assess altered reward processing in response to reward type (social, monetary) and reward phase (anticipation, delivery) in ASD.
Methods Functional magnetic resonance imaging during social and monetary reward anticipation and delivery was performed in 212 individuals with ASD (7.6-30.5 years) and 181 typically developing (TD) participants (7.6-30.8 years).
Results Across social and monetary reward anticipation, whole-brain analyses (p<0.05, family-wise error-corrected) showed hypoactivation of the right ventral striatum (VS) in ASD. Further, region of interest (ROI) analysis across both reward types yielded hypoactivation in ASD in both the left and right VS. Across delivery of social and monetary reward, hyperactivation of the VS in individuals with ASD did not survive correction for multiple comparisons. Reward type by diagnostic group interactions, and a dimensional analysis of autism trait scores were not significant during anticipation or delivery. Levels of attention-deficit/hyperactivity disorder (ADHD) symptoms did not affect reward processing in ASD.
Conclusions Our results do not support current theories linking atypical social interaction in ASD to specific alterations in processing of social rewards. Instead, they point towards a generalized hypoactivity of VS in ASD during anticipation of both social and monetary rewards. We suggest that this indicates attenuated subjective reward value in ASD independent of social content and ADHD symptoms.
CMOS sensors are the most promising candidates for the Micro-Vertex-Detector (MVD) of the CBM experiment at GSI, as they provide an unprecedented compromise between spatial resolution, low material budget, adequate radiation tolerance and readout speed. To study the integration of these sensors into a detector module, a so-called MVD-demonstrator has been developed. The demonstrator and its in-beam performance will be presented and discussed in this work.